Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Rating of “Buy” from Analysts

Capricor Therapeutics Inc (NASDAQ:CAPR) has been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $34.50.

Several equities research analysts have weighed in on CAPR shares. Oppenheimer reissued an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Maxim Group increased their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. HC Wainwright reaffirmed a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, November 14th. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, Cantor Fitzgerald lifted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th.

Insider Activity

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The trade was a 65.21 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Asset Management L.P. purchased a new stake in shares of Capricor Therapeutics in the 3rd quarter worth $3,806,000. Vanguard Group Inc. raised its holdings in shares of Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares in the last quarter. PFM Health Sciences LP purchased a new stake in Capricor Therapeutics in the third quarter worth about $2,324,000. State Street Corp grew its holdings in Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after acquiring an additional 111,291 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Capricor Therapeutics during the 2nd quarter valued at about $426,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Down 0.2 %

CAPR stock opened at $19.01 on Friday. The stock’s 50 day simple moving average is $18.03 and its 200 day simple moving average is $9.41. The stock has a market capitalization of $864.38 million, a PE ratio of -17.93 and a beta of 4.00. Capricor Therapeutics has a 12-month low of $2.90 and a 12-month high of $23.40.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.